Neurocrine Biosciences Inc.
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders. Its approved products include INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with… From the company’s description.
In fiscal 2025, Neurocrine Biosciences Inc. reported revenue of $2.86B, up 21.4% from fiscal 2024, and net income of $478.60M. Its operating margin was 21.6%, and operations generated $782.70M in cash. Over the twelve months to Jun 30, 2026, revenue was $3.37B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neurocrine Biosciences Inc. does
In the company’s own words
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders. Its approved products include INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia, and elagolix products for endometriosis and uterine fibroids, commercialized in collaboration with AbbVie. Neurocrine sells INGREZZA and CRENESSITY in the United States through specialty pharmacy channels; its customers include specialty pharmacies, wholesale distributors and specialty distributors. International partners market valbenazine under the DYSVAL and REMLEAS brands in Japan and select Asian markets. The company also develops a pipeline of drug candidates across its core therapeutic areas, including late-stage programs for major depressive disorder and schizophrenia. INGREZZA generated $2.51 billion in net product sales and CRENESSITY generated $301.2 million in 2025. Its website is www.neurocrine.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 914475
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neurocrine Biosciences Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neurocrine Biosciences Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neurocrine Biosciences Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neurocrine Biosciences Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neurocrine Biosciences Inc.'s last four quarterly filings that the numbers alone won't show?”